Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 9/2020

01-08-2020 | Kidney Cancer | Image of the Month

PSMA PET/CT for tyrosine-kinase inhibitor monitoring in metastatic renal cell carcinoma

Authors: L. M. Mittlmeier, M. Unterrainer, A. Todica, C. C. Cyran, S. Rodler, P. Bartenstein, C. G. Stief, H. Ilhan, M. Staehler

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 9/2020

Login to get access

Excerpt

With the introduction of tyrosine kinase and of checkpoint inhibitors for the treatment of metastatic renal cell carcinoma (RCC), overall survival has prolonged [1, 2]. As serum biochemistry or other immunomarkers are pending and are not routinely used to predict therapeutic efficacy, imaging remains the only valid biomarker so far. Early prediction of treatment response would be highly desirable for the individualization of patient management and improvement of therapeutic outcome. PSMA-targeted imaging has been successfully introduced into the staging of prostate cancer [3]. RCC is a hyper-vascularized cancer and has shown overexpression of PSMA. Thus, initial data show PSMA-targeted imaging to be promising in RCC [4, 5]. …
Literature
1.
2.
Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277–90.CrossRef
3.
Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA–PET in prostate cancer management. Nat Rev Urol. 2016;13:226.CrossRef
4.
Baccala A, Sercia L, Li J, Heston W, Zhou M. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology. 2007;70:385–90.CrossRef
5.
Metadata
Title
PSMA PET/CT for tyrosine-kinase inhibitor monitoring in metastatic renal cell carcinoma
Authors
L. M. Mittlmeier
M. Unterrainer
A. Todica
C. C. Cyran
S. Rodler
P. Bartenstein
C. G. Stief
H. Ilhan
M. Staehler
Publication date
01-08-2020
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 9/2020
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-019-04636-6

Other articles of this Issue 9/2020

European Journal of Nuclear Medicine and Molecular Imaging 9/2020 Go to the issue

Original Article

A kinetics-based approach to amyloid PET semi-quantification

Correction

Correction to: Imaging phenotype using 18F-fluorodeoxyglucose positron emission tomography-based radiomics and genetic alterations of pancreatic ductal adenocarcinoma

Image of the Month

[67Ga] Ga-citrate and COVID-19-associated pneumonia: an unexpected absence of uptake

Letter to the Editor

Coming back to the normal clinic: how has COVID-19 changed us?

Book Review

Adrian Dawkins (Ed). Ultrasound Q&A: Review for the Boards

Original Article

Initial experience with [18F]DPA-714 TSPO-PET to image inflammation in primary angiitis of the central nervous system